Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyObservational Study Published on 2021-12-012022-10-05 Journal: Alimentary pharmacology & therapeutics [Category] SARS, 임상, [키워드] Active disease adverse outcome adverse outcomes age anti-TNF Asymptomatic build cohort study Comorbidity Course COVID-19 COVID-19 in patient death disease evaluated General population greater help higher risk hospitalisation IBD identify Immune-mediated Inflammatory bowel disease inflammatory disease lower risk medication moderate multivariable analyses multivariable logistic regression obesity outcome outcomes Patient patients Pneumonia risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection severe COVID-19 significantly therapy ulcerative colitis ventilatory support was used [DOI] 10.1111/apt.16663 PMC 바로가기 [Article Type] Observational Study
Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD TreatmentReview Published on 2021-11-302022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Affect approved biologic clinical development Compliance Crohn’s disease cytokine Effectiveness Efficacy Future IBD immune pathways immunothrombosis implicated IMPROVE Inflammatory bowel disease inhibiting inhibitors Jak JAK inhibitor jak inhibitors Janus kinase medical need monoclonal antibodies pandemic Pathogenesis patients patients with COVID-19 question risk Safety safety profile several limitations Signaling small molecule Small molecules susceptibility the SARS-CoV-2 therapeutic response therapy Thromboembolic events thrombotic complication Treatment treatment strategy ulcerative colitis [DOI] 10.3390/jcm10235660 PMC 바로가기 [Article Type] Review
Long COVID in Inflammatory Bowel DiseasesCommunication Published on 2021-11-262022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] acute infection appear biologics Course COVID COVID-19 infection Crohn’s disease defined demographic characteristics evaluated females Frequency IBD individual Inflammatory bowel disease investigated Long long-lasting not differ occurred Pathologies Patient patients public health Quality of life recruited Rome SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected patient Symptom the patient two groups ulcerative colitis university [DOI] 10.3390/jcm10235575 PMC 바로가기 [Article Type] Communication
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsOriginal Article Published on 2021-11-212024-09-04 Journal: Journal of Crohn's and Colitis [Category] 대상포진, [키워드] re-treatment Tofacitinib ulcerative colitis [DOI] 10.1093/ecco-jcc/jjab065 PMC 바로가기 [Article Type] Original Article
Claudins: Beyond Tight Junctions in Human IBD and Murine ModelsOriginal Research Published on 2021-11-172023-08-30 Journal: Frontiers in Pharmacology [Category] E형 간염, [키워드] adoptive transfer colitis model claudins Crohn’s disease dextran sodium sulfate colitis model Inflammatory bowel disease ulcerative colitis [DOI] 10.3389/fphar.2021.682614 PMC 바로가기 [Article Type] Original Research
Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?Review Published on 2021-11-112022-10-29 Journal: International Review of Cell and Molecular Biology [Category] COVID-19, [키워드] acute respiratory distress acute respiratory syndrome approach ARDS circulation Complication coronavirus disease Coronavirus-2 Course COVID-19 Crohn’s disease Crohn’s disease effective Effectiveness expected gastrointestinal tract greater IBD Immunocompromised immunological immunosuppressive therapies immunosuppressive therapy Infection Inflammation Inflammatory bowel disease knowledge management medication pandemic pathogen Pathogens Patient patients provide reducing risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination severe disease course shown subject syndrome Therapeutic approach ulcerative colitis underlying condition vaccination Vaccine vaccine response [DOI] 10.3390/life11111220 PMC 바로가기 [Article Type] Review
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD RegistrySECURE-IBD 레지스트리에서 성인 IBD 환자의 COVID-19 결과에 대한 베돌리주맙의 영향Article Published on 2021-11-082022-09-12 Journal: Journal of Crohn's & colitis [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval adjusted odds ratio anti-TNF appear bowel Care comparable coronavirus disease Coronavirus disease 2019 covariates COVID-19 COVID-19 hospitalization Crohn’s disease determine Exploratory analysis Gastrointestinal symptom Hospitalization IBD Impact Inflammatory bowel disease International mechanical ventilation medication monotherapy multivariable analysis Necrosis outcome outcomes Patient patients patients with COVID-19 registry Safe severe COVID-19 Therapies therapy ulcerative ulcerative colitis vedolizumab [DOI] 10.1093/ecco-jcc/jjab071 PMC 바로가기 [Article Type] Article
Bioinformatics and system biology approaches to identify the diseasome and comorbidities complexities of SARS-CoV-2 infection with the digestive tract disorders소화관 장애와 SARS-CoV-2 감염의 질병 및 동반 질환 복잡성을 식별하기 위한 생물정보학 및 시스템 생물학 접근Article Published on 2021-11-052022-09-12 Journal: Briefings in Bioinformatics [Category] MERS, SARS, 진단, [키워드] Analysis approach association bioinformatics CEL Comorbidity complex interplay coronavirus 2 correlation COVID-19 COVID-19 pandemic COVID-19 positive patient COVID-19 positive patients Critical CRO differentially expressed differentially expressed gene Differentially expressed genes digestive digestive disorders digestive tract diseasome disorder disorders Effect enrichment analysis Evidence expression faece Faeces functional functional enrichment Gastrointestinal symptom gene regulatory network gene regulatory networks. Genes Health identify infected patient Infection influence Interaction live SARS-CoV-2 Messenger RNA overlap overlapping pathophysiology patients with COVID-19 protein-protein interaction raised Regulatory respiratory respiratory symptoms risk factor RNA-seq dataset SARS-CoV-2 SARS-COV-2 infection shown Symptom System biology therapeutic tissue tissues ulcerative colitis virus with COVID-19 [DOI] 10.1093/bib/bbab126 PMC 바로가기 [Article Type] Article
Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trialsMini review Published on 2021-11-012022-10-05 Journal: Respiratory medicine and research [Category] SARS, 임상, [키워드] 48 hours administration adverse event article assessment baseline clinical trial clinical trials cognitive conducted COVID-19 daily dose database Direct disease Diseases dose Effect Hospitalization initial Interaction itching lack nausea Non-smoker offer Patient potential risk protocol randomized trials receive receiving recent reported Result Safe Science selected Side-effect Side-effects systematic review therapy Tolerance Tourette syndrome transdermal Transdermal nicotine Treatment ulcerative colitis [DOI] 10.1016/j.resmer.2021.100844 [Article Type] Mini review
Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseasesArticle Published on 2021-11-012022-10-04 Journal: Acta pharmacologica Sinica [Category] SARS, 신약개발, [키워드] activating activity addition alcohol anti-inflammatory activity applied cause caused Cellular responses circulating Colitis Complication contribute disulfiram DSF dysregulated immune response effective Efficacy endotoxin gasdermin D glycoprotein immunosuppressive Infection Inflammation Inflammatory cytokine inflammatory disease inflammatory disorders Inflammatory response inhibitor lactoferrin life-threatening ligands Macrophage macrophage-targeting delivery macrophages multifunctional murine Neutralizing offer organ dysfunction patients pyroptosis Safe Sepsis therapeutic therapeutic effect therapeutic strategy treat Treatment ulcerative colitis various inflammatory disease [DOI] 10.1038/s41401-021-00770-w PMC 바로가기 [Article Type] Article